Weil Guides Bard In $200M Deal For Hemostat Maker Medafor
New Jersey-based C.R. Bard Inc. will pay some $200 million in cash to purchase Minneapolis-based hemostat firm Medafor Inc. through Bard's specialized surgical procedures unit Davol Inc., the companies said Monday....To view the full article, register now.
Already a subscriber? Click here to view full article